MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ACR stock logo

ACR

ACRES Commercial Realty Corp.

$10.45
0.24
 (2.35%)
Exchange:  NYSE
Market Cap:  74.52M
Shares Outstanding:  10.763M
Delayed data
Calculate ACR Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Real EstateView sector performance
Industry:  REIT – MortgageView industry performance
   
CEO:  Mark Steven Fogel
Full Time Employees:  4
Address: 
390 RXR Plaza
Uniondale
NY
11556
US
Website:  https://www.acresreit.com
ACRES Commercial Realty Corp. (ACR) functions as a real estate investment trust (REIT) based in Uniondale, New York, having been established in 2005. The firm’s primary objective is to generate, own, and administer various debt instruments related to commercial real estate, including mortgage loans, throughout the United States. ACR strategically allocates capital to a diverse range of assets tied to commercial properties. These investments encompass both variable and fixed-rate first lien mortgage loans, senior and junior participations in first mortgage loans, mezzanine financing, preferred equity investments, commercial mortgage-backed securities (CMBS), and direct equity or preferred equity stakes in commercial real estate. As a certified REIT for federal income tax purposes, the company typically avoids federal corporate income tax, contingent on distributing 100% of its taxable REIT income. Notably, the entity updated its legal name to ACRES Commercial Realty Corp. in February 2021, having previously been known as Exantas Capital Corp.

Click to read more…

Revenue Segmentation

MarketSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ACACR logoACRACRES Commercial Realty Corp.74.5M—43.52.0%
SUSUNS logoSUNSSunrise Realty Trust, Inc.79.1M6.04.86.4%
RPRPT logoRPTRithm Property Trust Inc.83.8M—1,0781.3%
GPGPMT logoGPMTGranite Point Mortgage Trust Inc.31.3M——-0.6%
SESEVN logoSEVNSeven Hills Realty Trust131.5M10.37.15.1%
CMCMTG logoCMTGClaros Mortgage Trust, Inc.169.3M——-13.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/30 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue91,13183,488165,903
Gross Profit52,21836,592159,336
EBITDA155,062135,784124,088
Operating Income20,67311,599102,387
Net Income22,39029,26721,316

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,196,1051,881,4672,162,364
Total Liabilities1,749,8901,431,8051,611,772
Total Stockholders Equity435,796439,128420,796
Total Debt1,720,4761,405,6301,590,880
Cash and Cash Equivalents83,44956,71385,958

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow45,60919,3854,102
Capital Expenditure0-8-165
Free Cash Flow45,60919,3773,937
Net Income21,84828,69521,316
Net Change in Cash-12,925-34,28328,355

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2027Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)61,913.789Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)72,606.210Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)67,260Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)20,685.920Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)23,924.331Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)20,830.996Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)11,100.390Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)13,658.735Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)11,215Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)9,556.276Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)11,206.631Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)10,381.453Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.670Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.840Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)1.500Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
197.982M  ?P/S
 (TTM)
: 
0.4
?Net Income
 (TTM)
: 
29.509M  ?P/E
 (TTM)
: 
-9.68
?Enterprise Value
 (TTM)
: 
1.862B  ?EV/FCF
 (TTM)
: 
577.06
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
148.89%
?ROE
 (TTM)
: 
3.31%  ?ROIC
 (TTM)
: 
1.99%
?Net Debt
 (TTM)
: 
1.348B  ?Debt/Equity
 (TTM)
: 
4.43
?P/B
 (TTM)
: 
0.17  ?Current Ratio
 (TTM)
: 
0

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
43.54Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates ACR intrinsic value between $47.98 – $51.08 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ACR valuation

Is ACRES Commercial Realty Corp. (ACR) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for ACRES Commercial Realty Corp. (ACR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ACR a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ACR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ACR’s P/E ratio?

You can see ACR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ACR?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ACR a good long-term investment?

Whether ACR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ACR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.35
MarketSnap

Trading Metrics:

Open: 10.35   Previous Close: 10.21
Day Low: 10.18   Day High: 10.52
Year Low: 9.91   Year High: 24.61
Price Avg 50: 13.44   Price Avg 200: 17.82
Volume: 49720   Average Volume: 40122

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
02-10-2026 10:15
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
02-10-2026 09:05
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
ACRES Commercial (ACR) Moves 9.5% Higher: Will This Strength Last?
01-10-2026 10:26
ACRES Commercial (ACR) Moves 9.5% Higher: Will This Strength Last?
ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program
29-09-2026 16:30
ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program
ACRES Commercial Realty: Why We Are Staying Neutral On ACRES Series C Preferred
31-07-2026 03:04
ACRES Commercial Realty: Why We Are Staying Neutral On ACRES Series C Preferred
ACRES Commercial Realty Corp. (ACR) Q2 2026 Earnings Call Transcript
30-07-2026 17:13
ACRES Commercial Realty Corp. (ACR) Q2 2026 Earnings Call Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read